ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
manuscript.docx (625.82 kB)

Drug Repurposing to Identify Therapeutics Against COVID 19 with SARS-Cov-2 Spike Glycoprotein and Main Protease as Targets: An in Silico Study

preprint
submitted on 07.04.2020, 05:20 and posted on 10.04.2020, 07:34 by arun kumar, Sharanya C.S, Abhithaj J, Sadasivan C

The total cases of novel corona virus (SARS-CoV-2) infections is more than one million and total deaths recorded is more than fifty thousand. The research for developing vaccines and drugs against SARS-CoV-2 is going on in different parts of the world. Aim of the present study was to identify potential drug candidates against SARS-CoV-2 from existing drugs using in silico molecular modeling and docking. The targets for the present study was the spike protein and the main protease of SARS-CoV-2. The study was able to identify some drugs that can either bind to the spike protein receptor binding domain or the main protease of SARS-CoV-2. These include some of the antiviral drugs. These drugs might have the potential to inhibit the infection and viral replication.

History

Email Address of Submitting Author

arunsrnd@gmail.com

Institution

kannur university

Country

India

ORCID For Submitting Author

0000-0002-2502-1719

Declaration of Conflict of Interest

no conflict of interest

Exports

Logo branding

Exports